Scancell HoldingsSCNLF 20 Current Ratio is 0.56 as of Oct. 2025, which is 93% below its 10-year median of 7.63. GuruFocus rates SCNLF with a GF Score™ of 20/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Scancell Holdings ranks worse than 90.32% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Scancell Holdings's current ratio for the quarter that ended in Oct. 2025 was 0.56.
Scancell Holdings has a current ratio of 0.56. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Scancell Holdings has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Scancell Holdings's Current Ratio or its related term are showing as below:
SCNLF'
s Current Ratio Range Over the Past 10 Years
Min: 0.43 Med: 7.63 Max: 24.05
Current: 0.56
During the past 13 years, Scancell Holdings's highest Current Ratio was 24.05. The lowest was 0.43. And the median was 7.63.
SCNLF's Current Ratio is ranked worse than 90.32% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs SCNLF: 0.56
Scancell Holdings (OTCPK:SCNLF) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Scancell Holdings Current Ratio Related Terms
Scancell Holdings Current Ratio Historical Data
* Premium members only.
The historical data trend for Scancell Holdings's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCNLF vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Scancell Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scancell Holdings Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scancell Holdings's Current Ratio distribution charts can be found below:
* The bar in red indicates where Scancell Holdings's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scancell Holdings (SCNLF) has a Current Ratio of 0.56 as of Oct. 2025. This is 93% below median its historical median of 7.63. Over the past decade, Scancell Holdings' Current Ratio has ranged from 0.43 to 24.05. According to the industry distribution chart, Scancell Holdings ranks #1279 out of 1416 companies in the Biotechnology industry, placing it in the top 90.3%.
Is Scancell Holdings' Current Ratio too high?
Scancell Holdings' current Current Ratio of 0.56 is 93% below median its 10-year median of 7.63. Over the past 10 years, this metric has ranged from a low of 0.43 to a high of 24.05. The Biotechnology industry median Current Ratio is 3.89. Scancell Holdings' value of 0.56 is 85.6% below this industry median. Based on the distribution chart, Scancell Holdings ranks #1279 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Scancell Holdings has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #1279 out of 1416 companies for Current Ratio. This places Scancell Holdings in the lower half of its industry. The industry median Current Ratio is 3.89. Scancell Holdings' value of 0.56 is 85.6% below this benchmark. Historically, Scancell Holdings' own Current Ratio has ranged from 0.43 to 24.05 over the past decade. While the company's 10-year median is 7.63 vs. the industry median of 3.89, Scancell Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scancell Holdings's current Current Ratio of 0.56 is 85.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scancell Holdings's current Current Ratio is 0.56, which is 93% below median its own 10-year median of 7.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current Current Ratio of 0.56. The current Current Ratio is 0.56, which is 93% below median its 10-year median of 7.63 and 85.6% below the Biotechnology industry median of 3.89. Scancell Holdings' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current Current Ratio is 0.56 as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
20GF Score
Get the complete analysis for SCNLF
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNLF has been successfully added to your 
